Literature DB >> 14739605

Potential mechanisms of leukemia cell resistance to TRAIL-induced apopotosis.

X-S Hao1, J-H Hao, F-T Liu, A C Newland, L Jia.   

Abstract

There are many factors contributing to the resistance to TRAIL (Tumor necrosis factor-related apoptosis-inducing ligand)-induced apoptosis. However, it is not clear whether the mechanism of resistance to TRAIL is constitutive or inductive. Therefore, the purpose of this study was to investigate the resistant mechanisms to TRAIL at different levels in the apoptotic pathway. The human T-lymphoblastic leukemic CEM cell line showed more resistant to TRAIL-induced apoptosis compared with the human chronic myeloid leukemic K562 cell line. Lower level of constitutive caspase-8 expression in the CEM cell line led to a poor response to both TRAIL-induced activation of caspase-3 and reduction in the mitochondrial membrane potential (DeltaPsim). There was no significant difference in the constitutive levels of NF-kappaB in CEM and K562 cell lines. However, CEM cells showed a faster response to TRAIL-induced NF-kappaB activation than K562 cells. TRAIL-induced regulation of Bcl-2 family of proteins included an up-regulation in Bcl-2/Bcl-XL and a down-regulation in Bax. IAPs, such as XIAP, cIAP-1, cIAP-2 and Survivin were all up-regulated during the treatment with TRAIL. In summary, our data suggest that the leukemic cells resistance to TRAIL-induced apoptosis might be due to the deficiency in the constitutive caspase-8 expression. Development of potential resistance to apoptosis by TRAIL can occur in both TRAIL-resistant and TRAIL-sensitive leukemic cells.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14739605     DOI: 10.1023/A:1026131425204

Source DB:  PubMed          Journal:  Apoptosis        ISSN: 1360-8185            Impact factor:   4.677


  5 in total

1.  Plumbagin treatment leads to apoptosis in human K562 leukemia cells through increased ROS and elevated TRAIL receptor expression.

Authors:  Jingping Sun; Robert J McKallip
Journal:  Leuk Res       Date:  2011-07-08       Impact factor: 3.156

2.  Preclinical relevance of dosing time for the therapeutic index of gemcitabine-cisplatin.

Authors:  X M Li; K Tanaka; J Sun; E Filipski; L Kayitalire; C Focan; F Lévi
Journal:  Br J Cancer       Date:  2005-05-09       Impact factor: 7.640

3.  Nucleofection optimization and in vitro anti-tumourigenic effect of TRAIL-expressing human adipose-derived mesenchymal stromal cells.

Authors:  Kamal Shaik Fakiruddin; Puteri Baharuddin; Moon Nian Lim; Noor Atiqah Fakharuzi; Nurul Ain Nasim M Yusof; Zubaidah Zakaria
Journal:  Cancer Cell Int       Date:  2014-11-26       Impact factor: 5.722

4.  The Interface between BCR-ABL-Dependent and -Independent Resistance Signaling Pathways in Chronic Myeloid Leukemia.

Authors:  Gabriela Nestal de Moraes; Paloma Silva Souza; Fernanda Casal de Faria Costas; Flavia Cunha Vasconcelos; Flaviana Ruade Souza Reis; Raquel Ciuvalschi Maia
Journal:  Leuk Res Treatment       Date:  2012-04-24

5.  Tumor necrosis factor-α attenuates starvation-induced apoptosis through upregulation of ferritin heavy chain in hepatocellular carcinoma cells.

Authors:  Xingrui Kou; Yingying Jing; Weijie Deng; Kai Sun; Zhipeng Han; Fei Ye; Guofeng Yu; Qingmin Fan; Lu Gao; Qiudong Zhao; Xue Zhao; Rong Li; Lixin Wei; Mengchao Wu
Journal:  BMC Cancer       Date:  2013-09-25       Impact factor: 4.430

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.